🧬 Aging Wiki

brca1

Properties1
aliasesBRCA1, breast cancer type 1 susceptibility protein, RNF53, BROVCA1

12 min read

BRCA1

BRCA1 (breast cancer type 1 susceptibility protein) is a 1,863-amino-acid nuclear E3 ubiquitin ligase and genome-caretaker that functions at the nexus of homologous recombination (HR), cell-cycle checkpoint control, and transcriptional regulation. Loss-of-function mutations confer substantially elevated lifetime cancer risk (precise risk figures in the Cancer Risk section are currently unverified — see no-fulltext-access note there). In the aging context, BRCA1 protein levels decline with age in breast epithelium and ovarian follicles, linking reduced HR fidelity to age-associated genomic instability and tissue depletion.

Identity

FieldValue
UniProtP38398 (BRCA1_HUMAN) — Swiss-Prot (manually curated)
NCBI Gene672
HGNC1100; symbol BRCA1 (alias RNF53)
EnsemblENSG00000012048
GenAgeEntry 61 — human aging gene (putative); GenAge notes premature aging in BRCA1-hypomorphic/TP53-heterozygous mice and centenarian allele-frequency signals 1
Mouse orthologBrca1 (one-to-one; used extensively in HR and aging studies)
Length1,863 amino acids (canonical isoform)
Chromosome17q21.31 — first mapped by genetic linkage in 1990 2
Molecular weight~208 kDa (predicted); runs anomalously on SDS-PAGE

Domain architecture

BRCA1 lacks catalytic domains of the canonical kinase/phosphatase family and instead acts as a scaffold and E3 ligase:

DomainResidues (approx.)Function
RING domain24–65Zn²⁺-coordinating RING-type zinc finger; obligate heterodimer with bard1 (BARD1, Q99728); together catalyze Lys-6-linked polyubiquitin chains on H2A and other substrates
Coiled-coil~1,391–1,424Mediates interaction with PALB2 (partner and localizer of BRCA2); critical for BRCA1-PALB2-BRCA2 HR axis
BRCT domain 11,642–1,736Phospho-peptide binding module; recognizes pSer motifs on CtIP, RBBP8, Abraxas, and BACH1/FANCJ
BRCT domain 21,756–1,855Tandem BRCT pair with BRCT1; cancer-associated mutations here frequently destabilize the fold
NLS (multiple)scatteredNuclear import; BRCA1 is predominantly nuclear but shuttles during apoptosis

The RING domain is non-functional in isolation: BRCA1 requires obligate heterodimer formation with BARD1 for E3 ligase activity 3. needs-replication — precise Lys-6-linkage substrate specificity in vivo remains incompletely characterized.

BRCA1 complexes

BRCA1 assembles into at least three partially-non-overlapping nuclear complexes that mediate distinct DNA repair sub-steps:

ComplexKey partnersPrimary function
BRCA1-AAbraxas (ABRAXAS1), RAP80 (UIMC1), MERIT40 (NBA1), BRCC36 (KIAA0157), BRERecruited to ubiquitinated H2A at DSB flanks via RAP80 UIM domains; scaffolds BRCA1 at damage sites; controls DSB end resection rate
BRCA1-BBACH1/FANCJ (BRIP1)Facilitates replication fork restart and HR; BACH1 is a 5’→3’ DNA helicase
BRCA1-CCtIP (RBBP8), MRN (MRE11-RAD50-NBN)Directly promotes 5’→3’ end resection, generating ssDNA overhangs that recruit RPA then RAD51

Complex membership is regulated by the phosphorylation state of Abraxas/CtIP BRCT-binding motifs; ATM-mediated phosphorylation licenses BRCA1-A and BRCA1-C assembly at DSBs 4. unsourced — quantitative kinetics of complex switching at individual foci are not established in primary sources I have confirmed.

BRCA1 in homologous recombination

The canonical demonstration that BRCA1 is required for HR came from Moynahan et al. 1999, who showed that mouse embryonic cells carrying a targeted Brca1 deletion repaired I-SceI-induced DSBs by HR at ~10-fold lower efficiency than controls, with no change in NHEJ frequency 5.

Mechanism (broad consensus, details require verification):

  1. ATM / ATR phosphorylate BRCA1 at multiple Ser residues within minutes of DSB induction.
  2. Phospho-BRCA1 co-localizes with γ-H2AX foci, recruiting the BRCA1-C complex.
  3. BRCA1-CtIP-MRN promotes Mre11 nuclease-dependent resection, generating 3’ ssDNA overhangs.
  4. BRCA1 facilitates RPA displacement by RAD51 via the BRCA1-PALB2-BRCA2-RAD51 filament axis.
  5. RAD51-coated ssDNA invades the sister chromatid, enabling high-fidelity repair.

BRCA1 thus acts upstream of RAD51 loading — it is not a recombinase but a licensing and scaffolding factor for HR. Loss of function forces cells into error-prone NHEJ or microhomology-mediated end-joining (MMEJ), increasing mutational burden.

DimensionStatus
Pathway conserved in humans?yes — BRCA1 and all core HR partners are highly conserved; human BRCA1 rescues mouse Brca1-null lethality
Phenotype conserved in humans?yes — BRCA1 germline mutation carriers accumulate somatic mutations and chromosomal instability at elevated rates
Replicated in humans?yes — somatic HR deficiency (“BRCAness”) confirmed by genomic scar signatures (HRD score) in tumor sequencing

PARP inhibitor synthetic lethality

The two simultaneous 2005 Nature papers by Bryant et al. and Farmer et al. established the synthetic lethal relationship between BRCA1/2 deficiency and PARP inhibition — one of the most clinically successful applications of synthetic lethality in oncology 6 7.

Mechanism: BRCA1/2-deficient cells rely on PARP1-mediated single-strand break (SSB) repair to resolve replication-associated SSBs. PARP inhibitors trap PARP1-DNA complexes at SSBs; when these are encountered by replication forks, SSBs are converted to DSBs. In HR-proficient cells, these replication-associated DSBs are repaired by RAD51-dependent sister chromatid exchange. In BRCA1/2-deficient cells, lacking functional HR, DSBs persist or are misrepaired by error-prone NHEJ/SSA, causing chromosomal instability and cell death 6 7. Note: Bryant 2005 demonstrated this primarily for BRCA2-deficient cells; Farmer 2005 demonstrated it for both BRCA1- and BRCA2-deficient mouse ES cells and proposed BRCA1 sensitivity based on siRNA knockdown in human cells (full BRCA1-deficient ES cell data described as “unpublished” in the 2005 paper).

Clinical translation: Four PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) are FDA-approved for BRCA1/2-mutated cancers (ovarian, breast, pancreatic, prostate — indications vary by drug). This represents a druggability-tier 1 intervention at the level of the pathway, though BRCA1 itself has no approved direct inhibitor.

Note: PARP inhibitors exploit BRCA1 loss rather than BRCA1 activity — they are not BRCA1 modulators. Druggability tier 3 in the frontmatter reflects the direct-targeting assessment of BRCA1 protein.

BRCA1 mutations and cancer risk

BRCA1 is classified as a high-penetrance tumor suppressor following classic two-hit kinetics: germline heterozygous pathogenic variants in BRCA1 confer substantially elevated lifetime cancer risk, with somatic loss-of-heterozygosity (LOH) or promoter methylation completing the “second hit” in tumors 8.

Approximate lifetime cancer risk estimates for BRCA1 germline pathogenic variant carriers no-fulltext-access — stated citation (Foulkes 2014 NEJM, DOI 10.1056/NEJMra1306063) is confirmed invalid: the DOI returns HTTP 404 at doi.org and is absent from Crossref, PubMed, Europe PMC, and Semantic Scholar. The DOI appears to be fabricated or mis-transcribed. Risk figures below are from the seeder extraction and must not be relied upon until a valid primary source is identified and verified:

CancerSeeder-reported estimatePopulation baselineSource status
Breast (female)~65–72% by age 80~12%no-fulltext-access — unverified
Ovarian (epithelial)~44–46% by age 80~1.3%no-fulltext-access — unverified
Contralateral breast~40–60% (10-year cumulative after first diagnosis)—no-fulltext-access — unverified

The widely-cited Antoniou et al. 2003 (PMID 12677558, Am J Hum Genet) meta-analysis reported BRCA1 carrier lifetime breast cancer risk of ~65% and ovarian risk of ~39%; Chen & Parmigiani 2007 (PMID 17452630, J Clin Oncol) reported ~57% and ~40% respectively. These are candidate replacement citations pending user decision on which source to use. needs-canonical-id — a valid DOI and verified primary source are required before relying on any specific percentage.

BRCA1-associated breast cancers are predominantly triple-negative (ER−/PR−/HER2−) and high-grade. This is mechanistically linked to BRCA1’s role in maintaining estrogen receptor alpha (ESR1) expression and normal luminal differentiation. no-fulltext-access — this claim was footnoted to the invalid Foulkes DOI; requires a verified replacement citation. needs-replication — the ESR1 regulation link is additionally based on cell-line and mouse data.

Most pathogenic variants are frameshift or nonsense mutations (loss of protein). Missense variants in the BRCT domains are frequently pathogenic; missense in the RING domain have variable classification (many VUSs remain). unsourced — precise variant class distribution figures require a ClinVar/LOVD-derived citation.

Aging relevance

BRCA1 expression declines with age

BRCA1 transcript and protein levels decrease in aging breast epithelium and in the aging ovary 9. This age-associated decline is proposed to reduce HR fidelity in normal (non-malignant) tissue, contributing to the age-related accumulation of somatic mutations and structural variants that underlies cancer risk and tissue dysfunction.

Ovarian aging: Oktay and colleagues demonstrated that BRCA1-mutant women show accelerated ovarian aging (lower ovarian reserve, earlier menopause), consistent with a role for BRCA1-dependent DSB repair in protecting primordial-follicle oocytes from accumulated oxidative DSBs 9 10.

DimensionStatus
BRCA1 age-decline in humans?yes — transcript and protein data in breast and ovarian tissue 9
HR efficiency decline with age?partial — indirect evidence via somatic mutation accumulation; direct assay data in aged non-malignant human tissue limited
Replicated mechanistically in humans?no — most mechanistic aging data from mouse models

needs-human-replication — direct measurement of HR efficiency (e.g., via chromosomal scar signatures) in normal aged human tissue as a function of BRCA1 expression is not established.

BRCA1 deficiency, stem cell senescence, and genomic instability

BRCA1 loss in mammary stem cells (MaSCs) triggers p16Ink4a-mediated senescence, impairing regenerative capacity 11. This is mechanistically relevant to stem-cell-exhaustion: accumulated HR deficiency → unresolved DSBs → p21/p16 activation → senescence. Conversely, p16 loss rescues BRCA1-deficient MaSC function in mouse models 11.

This connects BRCA1 to two hallmarks simultaneously: genomic-instability (upstream driver) and stem-cell-exhaustion (downstream consequence).

GenAge status

GenAge entry 61 (human gene database): BRCA1 is listed as a putative human aging gene. Supporting evidence: (1) mice hypomorphic for Brca1 and heterozygous for Trp53 display premature aging signs at ~8 months; (2) centenarian studies suggest differences in BRCA1 allele frequencies vs. controls 1. Evidence quality is limited — no large prospective human aging cohort has directly tested BRCA1 variant effects on biological age trajectories. needs-human-replication.

Key interactors

  • bard1 — RING-domain obligate heterodimer; required for E3 ligase activity and nuclear retention
  • palb2 — coiled-coil-mediated; bridges BRCA1 to brca2 and RAD51 for HR execution
  • brca2 — downstream in the BRCA1-PALB2-BRCA2-RAD51 axis; mediates RAD51 filament assembly
  • rad51 — recombinase loaded by BRCA2; HR effector
  • atm / ATR — upstream kinases that phosphorylate and activate BRCA1 post-DSB
  • abraxas1 (ABRAXAS1) — BRCA1-A complex scaffold; binds BRCT domain via phospho-Ser motif
  • rap80 (UIMC1) — RAP80; recruits BRCA1-A to K63-ubiquitinated H2A at DSBs
  • ctip (RBBP8) — BRCA1-C complex; promotes resection
  • tp53bp1 (53BP1) — competes with BRCA1 for DSB end choice (53BP1 favors NHEJ; BRCA1 favors HR); antagonistic interplay is cell-cycle-regulated

Pathway membership

Hallmark mapping

HallmarkMechanism
genomic-instabilityLoss of HR → increased mutagenesis, chromosomal rearrangements, aneuploidy; accumulates with age as BRCA1 declines
stem-cell-exhaustionBRCA1-deficient MaSCs undergo p16-mediated senescence, depleting regenerative pool 11
cellular-senescenceUnresolved DSBs in BRCA1-deficient cells activate p21/p16 → SASP-secreting senescent cells

Limitations and gaps

  • needs-human-replication — HR efficiency in normal aged non-malignant human tissue as a function of BRCA1 expression: no direct assay data in primary literature confirmed here.
  • needs-replication — Precise Lys-6-linked polyubiquitin substrate specificity of the BRCA1-BARD1 E3 ligase in vivo is incompletely characterized.
  • contradictory-evidence — The scope of BRCA1’s role in nhej vs. HR choice is debated; some studies show context-dependent NHEJ involvement.
  • dose-response-unclear — Relationship between degree of BRCA1 expression decline with age and quantitative change in HR efficiency in normal tissue is not established.
  • unsourced — BRCA1 pathogenic variant class distribution figures (frameshift vs. missense vs. nonsense) cited in clinical discussions should be sourced from ClinVar or LOVD.
  • DOI 10.1056/NEJMra1306063 (stated as “Foulkes 2014, NEJM”): confirmed non-existent — HTTP 404 at doi.org, absent from Crossref, PubMed, Europe PMC, and Semantic Scholar as of 2026-05-05 verification pass. The DOI is fabricated or mis-transcribed. All claims attributed to this source (lifetime breast/ovarian cancer risk percentages; triple-negative phenotype mechanistic link to ESR1) are currently unsourced. Candidate replacement citations are noted in the [^foulkes2014] footnote. no-fulltext-access needs-canonical-id

Footnotes

Footnotes

  1. GenAge human database entry 61 (BRCA1) · https://genomics.senescence.info/genes/entry.php?hgnc=BRCA1 · accessed 2026-05-05 · putative human aging gene; premature aging in Brca1-hypomorphic/Trp53+/− mice; centenarian allele-frequency signals (references 37, 1838, 416 in GenAge) ↩ ↩2

  2. hall-1990-brca1-17q21-linkage · doi:10.1126/science.2270482 · n=~329 individuals (23 families) · observational (genetic linkage) · LOD score >3 · model: familial early-onset breast cancer pedigrees · archive: in metadata (not_oa; no PDF downloaded) ↩

  3. doi:10.1074/jbc.M109884200 · in-vitro (biochemical) · RING heterodimer requirement for E3 activity established · model: purified recombinant human BRCA1-BARD1 · needs-replication not confirmed in archive ↩

  4. doi:10.1016/j.molcel.2007.03.012 · in-vitro + in-vivo (human cell lines) · BRCA1-A complex assembly and RAP80 recruitment to ubiquitinated H2A · model: U2OS and MCF7 cells + mouse xenografts · archive: not confirmed in archive lookup ↩

  5. moynahan-1999-brca1-hr · doi:10.1016/s1097-2765(00)80202-6 · n=ES cell lines (in-vitro) · randomized (I-SceI DSB assay) · HR frequency ~10-fold reduced in Brca1-null cells · model: mouse embryonic stem cells · archive: pending download (bronze OA) ↩

  6. bryant-2005-parp-brca2-synthetic-lethality · doi:10.1038/nature03443 · n=cell lines (V79, V-C8 BRCA2-deficient, MCF7, MDA-MB-231, SW480SN.3) + mouse xenografts (40 CD-1 nude mice, 10/group) · in-vitro + in-vivo · BRCA2-deficient cells selectively killed by PARP inhibitors NU1025 and AG14361; BRCA2 deficiency confirmed to be the sensitivity determinant regardless of p53 status · model: CHO-derived V79/V-C8 cells; breast cancer cell lines; xenograft · archive: PDF available at · cited_by: 5,038 ↩ ↩2

  7. farmer-2005-parp-brca-targeting · doi:10.1038/nature03445 · n=ES cell lines (BRCA1- and BRCA2-deficient mouse ES cells, isogenic WT controls) + xenografts (BALB/c-nude mice, 2×10⁶ ES cells s.c.; KU0058684 15 mg/kg i.p.) · in-vitro + in-vivo · BRCA1- and BRCA2-deficient ES cells selectively killed by PARP inhibitors KU0058684 (SF50 = 35 nM for BRCA1-KO ES cells vs ~2 µM WT) and KU0058948; tumour growth inhibition in xenografts (P = 0.03 vs vehicle; P = 0.01 vs WT xenograft) · model: mouse embryonic stem cells with homozygous Brca1 or Brca2 deletion · note: cell lines listed as “MDA-MB-436, EUFA423” in earlier wiki version were incorrect — those are not Farmer 2005 cell lines · archive: PDF available at · cited_by: 6,496 ↩ ↩2

  8. CITATION INVALID — doi:10.1056/NEJMra1306063 returns HTTP 404 at doi.org; absent from Crossref, PubMed, Europe PMC, and Semantic Scholar as of 2026-05-05. This DOI does not exist. All claims footnoted here (lifetime cancer risk percentages; ESR1/triple-negative breast cancer mechanistic link) are unsourced until a valid replacement citation is identified. no-fulltext-access needs-canonical-id — do not cite this footnote for any claim. Candidate replacements: Antoniou et al. 2003 PMID 12677558 (meta-analysis, lifetime risk estimates); Chen & Parmigiani 2007 PMID 17452630 (updated estimates). ↩

  9. turan-2020-brca-atm-ovarian-aging · doi:10.1093/humupd/dmz043 · review + meta-analysis · BRCA1/2 mutations accelerate ovarian aging (reduced reserve, earlier menopause) · model: human cohort + mechanistic mouse data · archive: pending download (bronze OA) · cited_by: 164 ↩ ↩2 ↩3

  10. doi:10.1095/biolreprod.115.132290 · review · BRCA mutations, DNA repair deficiency, and ovarian aging · model: human + mouse · archive: pending download (bronze OA) · cited_by: 159 ↩

  11. doi:10.1080/15384101.2017.1295185 · in-vivo (mouse) + in-vitro · p16 loss rescues functional decline of Brca1-deficient mammary stem cells · model: Brca1-conditional KO mice · archive: pending download (bronze OA) · cited_by: 22 (low; prioritize replication check) ↩ ↩2 ↩3

Graph View

Backlinks